357 related articles for article (PubMed ID: 28577951)
21. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
22. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.
Kashima J; Okuma Y; Shimizuguchi R; Chiba K
Cancer Immunol Immunother; 2018 Jan; 67(1):61-65. PubMed ID: 28913619
[TBL] [Abstract][Full Text] [Related]
23. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
[TBL] [Abstract][Full Text] [Related]
24. [Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma].
Palacios Zabalza I; López de Torre Querejazu A; Santos Ibañez A
Farm Hosp; 2014 Apr; 38(2):145-7. PubMed ID: 24669900
[TBL] [Abstract][Full Text] [Related]
25. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome.
Shah KM; Rancour EA; Al-Omari A; Rahnama-Moghadam S
Dermatol Online J; 2018 Jun; 24(6):. PubMed ID: 30142712
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.
Gracia-Cazaña T; Padgett E; Calderero V; Oncins R
Dermatol Online J; 2021 Mar; 27(3):. PubMed ID: 33865285
[TBL] [Abstract][Full Text] [Related]
27. Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer.
Iyoda T; Kurita N; Takada A; Watanabe H; Ando M
Am J Case Rep; 2018 Mar; 19():360-364. PubMed ID: 29581417
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.
Schwarz M; Kocher F; Niedersuess-Beke D; Rudzki J; Hochmair M; Widmann G; Hilbe W; Pircher A
Clin Lung Cancer; 2019 May; 20(3):e247-e250. PubMed ID: 30635258
[No Abstract] [Full Text] [Related]
29. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
30. A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis.
Richard K; Weslow J; Porcella SL; Nanjappa S
Cancer Control; 2017; 24(5):1073274817729069. PubMed ID: 28975824
[TBL] [Abstract][Full Text] [Related]
31. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
Lung Cancer; 2019 Apr; 130():159-161. PubMed ID: 30885338
[TBL] [Abstract][Full Text] [Related]
32. Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
Nayar N; Briscoe K; Fernandez Penas P
J Immunother; 2016 Apr; 39(3):149-52. PubMed ID: 26938948
[TBL] [Abstract][Full Text] [Related]
33. A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.
Jodai T; Yoshida C; Sato R; Kakiuchi Y; Sato N; Iyama S; Kimura T; Saruwatari K; Saeki S; Ichiyasu H; Fujii K; Tomita Y
Immun Inflamm Dis; 2019 Mar; 7(1):3-6. PubMed ID: 30461210
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status.
Chandrakanth MV; Noronha V; Joshi A; Patil V; Mahajan A; Prabhash K
Indian J Cancer; 2017; 54(1):55-56. PubMed ID: 29199664
[No Abstract] [Full Text] [Related]
35. [Unexpected adverse events of immunotherapies in non-small cell lung cancer: About 2 cases].
de Chabot G; Justeau G; Pinquié F; Nadaj-Pakleza A; Hoppé E; Hureaux J; Urban T
Rev Pneumol Clin; 2017 Dec; 73(6):326-330. PubMed ID: 29169677
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice.
Domagała-Kulawik J
Adv Respir Med; 2018; 86(3):. PubMed ID: 29960281
[TBL] [Abstract][Full Text] [Related]
37. [Psoriasis and Psoriatic Arthritis Induced by Nivolumab in a Patient with Advanced Non-Small-Cell Lung Cancer].
Sugiura Y; Fujimoto H; Yamamoto M; Nomura H; Hashizume T; Kawai O; Araki N; Kawakami K; Sueki H; Fusegawa H; Ohkubo Y; Nemoto E
Gan To Kagaku Ryoho; 2017 Sep; 44(9):787-789. PubMed ID: 28912410
[TBL] [Abstract][Full Text] [Related]
38. Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.
Yasuda Y; Urata Y; Tohnai R; Ito S; Kawa Y; Kono Y; Hattori Y; Tsuda M; Sakuma T; Negoro S; Satouchi M
Intern Med; 2018 May; 57(9):1269-1272. PubMed ID: 29279482
[TBL] [Abstract][Full Text] [Related]
39. Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report.
Takahashi N; Tsuji K; Tamiya H; Shinohara T; Kuroda N; Takeuchi E
Lung Cancer; 2018 Aug; 122():22-24. PubMed ID: 30032835
[TBL] [Abstract][Full Text] [Related]
40. IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma.
Kishi S; Minato M; Saijo A; Murakami N; Tamaki M; Matsuura M; Murakami T; Nagai K; Abe H; Nishioka Y; Doi T
Intern Med; 2018 May; 57(9):1259-1263. PubMed ID: 29279511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
